유도만능줄기세포(iPSC) 생산 시장 : 공정별, 제품 및 서비스별, 용도별, 최종 용도별, 세계 예측(2024-2032년)

Global Induced Pluripotent Stem Cells Production Market will grow at a 9.8% CAGR between 2023 and 2032, owing to the escalating research and development initiatives in regenerative medicine. Collaborations between research institutions and biopharmaceutical companies are intensifying, fostering technological advancements, and accelerating iPSC-based therapeutic applications. As the synergy between academia and industry strengthens, the market will witness substantial growth, propelled by the combined efforts to harness the potential of iPSCs for innovative solutions in personalized medicine and regenerative therapies.

For instance, in 2023, SCG Therapy inaugurated a state-of-the-art cell therapy manufacturing facility and R&D center in Singapore. Leveraging advanced cell therapy manufacturing and off-the-shelf human-induced pluripotent stem cell (iPSC) technology, the facility aims to supply cell therapy products to partner hospitals across Asia Pacific, Europe, and North America, enhancing SCG's capabilities in the global market. This move marks SCG's significant contribution to strengthening the induced pluripotent stem cells production industry, augmenting production capabilities to meet global demand and address increasing patient needs.

The induced pluripotent stem cells production market is fragmented based on end-use, application, and region.

The research and academic institutes segment will establish a significant market foothold by 2032, fueled by the increasing focus on iPSCs for innovative research and therapeutic applications. Research institutions leverage iPSC technology for disease modeling, drug discovery, and regenerative medicine studies, significantly contributing to the market's growth. With a surge in collaborations and funding for stem cell research, the research and academic institutes segment will stand as a key driver in the iPSC production market.

The regenerative medicine segment will witness a substantial upswing by 2032, attributed to the growing application of iPSCs in regenerative therapies for treating various medical conditions. As regenerative medicine gains traction for its potential in tissue repair and organ regeneration, iPSCs play a pivotal role in advancing these innovative therapeutic approaches. The regenerative medicine sector's increasing focus on iPSC-based solutions will position it as a key contributor to market expansion.

Europe induced pluripotent stem cells production industry will register a notable CAGR during 2023 and 2032 due to its robust investments in biomedical research, favorable regulatory frameworks, and an increasing emphasis on regenerative medicine. European countries exhibit a significant commitment to advancing iPSC technology for clinical applications, driving market growth. With a thriving biotechnology landscape and strategic collaborations, Europe will stand as a key contributor to shaping the share of iPSC production.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data validation
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Induced pluripotent stem cells production industry 360 degree synopsis, 2018 - 2032 (USD Million)
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Process trends
  • 2.1.4 Product & service trends
  • 2.1.5 Application trends
  • 2.1.6 End-use trends

Chapter 3 Induced Pluripotent Stem Cells Production Market Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Million)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of cancer
    • 3.2.1.2 Significant therapeutic potential of iPSC
    • 3.2.1.3 Increased applications in drug discovery & development
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 High production cost
• 3.3 Growth potential analysis
  • 3.3.1 By process
  • 3.3.2 By product & services
  • 3.3.3 By application
  • 3.3.4 By end-use
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis, 2023
• 4.3 Competitive analysis of major market players, 2023
• 4.4 Competitive positioning matrix, 2023
• 4.5 Strategic dashboard, 2023

Chapter 5 Induced Pluripotent Stem Cells Production Market Estimates and Forecast, By Process, 2018-2032 (USD Million)

• 5.1 Key trends, by process
• 5.2 Manual iPSC production process
• 5.3 Automated iPSC production process

Chapter 6 Induced Pluripotent Stem Cells Production Market Estimates and Forecast, By Product & Service, 2018-2032 (USD Million)

• 6.1 Key trends, by product & service
• 6.2 Products
  • 6.2.1 Consumables & kits
  • 6.2.2 Instruments/ devices
  • 6.2.3 Automated platforms
• 6.3 Service

Chapter 7 Induced Pluripotent Stem Cells Production Market Estimates and Forecast, By Application, 2018-2032 (USD Million)

• 7.1 Key trends, by application
• 7.2 Drug development & discovery
• 7.3 Regenerative medicine
• 7.4 Toxicology studies
• 7.5 Other applications

Chapter 8 Induced Pluripotent Stem Cells Production Market Estimates and Forecast, By End-use, 2018-2032 (USD Million)

• 8.1 Key trends, by end-use
• 8.2 Pharmaceutical & biotechnology companies
• 8.3 Research & academic institutes
• 8.4 Contract research organizations

Chapter 9 Induced Pluripotent Stem Cells Production Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Lonza
• 10.2 Axol Biosciences Ltd.
• 10.3 Evotec SE
• 10.4 Hitachi Ltd.
• 10.5 Merck KGaA
• 10.6 REPROCELLS, Inc.
• 10.7 Fate Therapeutics
• 10.8 Thermo Fisher Scientific, Inc.
• 10.9 StemCellsFactory III
• 10.10 Applied StemCells, Inc.
• 10.11 Creative Biolabs
• 10.12 Bio-Techne Corporation